How have OCEAW shares performed in 2024?

Ocean Biomedical's stock was trading at $0.0380 at the beginning of 2024. Since then, OCEAW stock has increased by 156.8% and is now trading at $0.0976. View the best growth stocks for 2024 here .

How do I buy shares of Ocean Biomedical?

Shares of OCEAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OCEAW

Ocean Biomedical (OCEAW) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free OCEAW Stock Alerts

$0.10

+0.01 (+11.42%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.10
▼
$0.14
50-Day Range: $0.02
▼
$0.59
52-Week Range: $0.02
▼
$0.70

Volume: 4,686 shs
Average Volume: 54,734 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Ownership SEC Filings Short Interest Social Media

Get Ocean Biomedical alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Ocean Biomedical

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.

OCEAW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OCEAW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive OCEAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocean Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:OCEAW
CUSIP: N/A
CIK: 1869974
Web: www.oceanbiomedical.com
Phone: 401-444-7375
Fax: N/A
Employees: 9
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Ms. Elizabeth Ng M.B.A. (Age 65)
CEO & Director
Mr. Gurinder Singh Kalra M.B.A. (Age 56)
Chief Financial Officer
Dr. Inderjote Kathuria M.B.A. (Age 55)
M.D., Chief Strategy Officer
Mr. Daniel Behr M.B.A. (Age 64)
Exec. VP & Head of External Innovation and Academic Partnerships
Dr. Chirinjeev Baboo Kathuria M.B.A. (Age 57)
M.D., Founder & Exec. Chairman
Dr. Jack A. Elias M.D.
Founder & Chairman of Scientific Advisory Board
Dr. Jonathan Kurtis M.D. (Age 54)
Ph.D., Founder, Chairman of Scientific Advisory Board & Director
Mr. Robert John Sweeney
Chief Accounting Officer
Mr. Kevin Kertscher
Communications Director

Key Competitors

View All Competitors

OCEAW Stock Analysis - Frequently Asked Questions

How have OCEAW shares performed in 2024?: Ocean Biomedical's stock was trading at $0.0380 at the beginning of 2024. Since then, OCEAW stock has increased by 156.8% and is now trading at $0.0976.
View the best growth stocks for 2024 here.
How do I buy shares of Ocean Biomedical?: Shares of OCEAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCEAW) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial